TKL Research Agrees to Sell Clinical Trials Division
TKL’s existing Research Clinics Division will continue to operate as TKL Research, Inc.
Rochelle Park, N.J. - TKL Research, a dermatology specialty clinical research organization (CRO), announced today that it has signed an agreement to sell its Clinical Trials Division (CTD) to QuintilesIMS. Upon closing, TKL’s CTD will become part of Novella Clinical, a Quintiles company. Moving forward, TKL Research will retain its Research Clinics Division (RCD) as TKL Research, Inc., which operates full-service inpatient and outpatient Phase I facilities in northern New Jersey.
The transaction, which is subject to standard and customary closing conditions, is expected to close in the fourth quarter of 2016.
“It’s exciting to see CTD take this next step in its strategic growth plan,” said Jon C. Anderson, Ph.D., President and CEO of TKL Research. “With this deal, we will continue our focus on providing our inpatient and outpatient Phase I services. We look forward to the future of TKL’s Research Clinics Division as we begin to operate independently as TKL Research, Inc.”
Serving as a full-service, global, dermatology CRO since 1995, TKL is headquartered in Rochelle Park, New Jersey and has offices in Fairlawn, New Jersey.
About TKL Research, Inc.TKL Research provides comprehensive clinical trial management services for Phase 1-4 clinical research studies, including an inpatient Phase 1 facility and outpatient specialized research clinics. TKL has broad capabilities that include a unique patient recruitment paradigm to shorten timelines as well as minimal staff turnover and deep expertise in dermatologic indications.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
